TY - JOUR
T1 - Expression of interferon alpha/beta receptor in human hepatocellular carcinoma.
AU - Kondo, M.
AU - Nagano, H.
AU - Sakon, M.
AU - Yamamoto, H.
AU - Morimoto, O.
AU - Arai, I.
AU - Miyamoto, A.
AU - Eguchi, H.
AU - Dono, K.
AU - Nakamori, S.
AU - Umeshita, K.
AU - Wakasa, K.
AU - Ohmoto, Y.
AU - Monden, M.
PY - 2000/7
Y1 - 2000/7
N2 - Interferon-alpha (IFNalpha) plays a crucial role in the antiproliferation and immunoregulatory activity through the specific cell surface receptor, interferon-alpha/beta receptor (IFNalpha/betaR). We examined the immunohistochemical expression of IFNalpha/betaR in 91 hepatocellular carcinoma (HCC), HCV-related chronic hepatitis (n=38) and cirrhosis (n=53), dysplastic nodules (n=5), and normal liver (n=9). The level of IFNalpha/betaR increased in chronic hepatitis and cirrhosis compared with normal liver. All the dysplastic nodules showed moderate or high expression. In HCCs, 26% (24/91) of patients showed high IFNalpha/betaR expression while the remaining 38% (35/91) showed moderate, and 35% (32/91) no or faint expression. Clinicopathological survey demonstrated a significant correlation between IFNalpha/betaR expression and differentiation of carcinoma (P=0.0008) although there was no correlation between IFNalpha/betaR expression in HCC and survival or disease-free survival. Thus, IFNalpha/betaR was expressed not only in chronic hepatitis or liver cirrhosis but in HCC and its expression was significantly correlated with tissue differentiation of carcinoma.
AB - Interferon-alpha (IFNalpha) plays a crucial role in the antiproliferation and immunoregulatory activity through the specific cell surface receptor, interferon-alpha/beta receptor (IFNalpha/betaR). We examined the immunohistochemical expression of IFNalpha/betaR in 91 hepatocellular carcinoma (HCC), HCV-related chronic hepatitis (n=38) and cirrhosis (n=53), dysplastic nodules (n=5), and normal liver (n=9). The level of IFNalpha/betaR increased in chronic hepatitis and cirrhosis compared with normal liver. All the dysplastic nodules showed moderate or high expression. In HCCs, 26% (24/91) of patients showed high IFNalpha/betaR expression while the remaining 38% (35/91) showed moderate, and 35% (32/91) no or faint expression. Clinicopathological survey demonstrated a significant correlation between IFNalpha/betaR expression and differentiation of carcinoma (P=0.0008) although there was no correlation between IFNalpha/betaR expression in HCC and survival or disease-free survival. Thus, IFNalpha/betaR was expressed not only in chronic hepatitis or liver cirrhosis but in HCC and its expression was significantly correlated with tissue differentiation of carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0034223548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034223548&partnerID=8YFLogxK
U2 - 10.3892/ijo.17.1.83
DO - 10.3892/ijo.17.1.83
M3 - Article
C2 - 10853022
AN - SCOPUS:0034223548
SN - 1019-6439
VL - 17
SP - 83
EP - 88
JO - International journal of oncology
JF - International journal of oncology
IS - 1
ER -
